Disto Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 4.56 Cr
- Company Age 22 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.49 Cr
- Satisfied Charges ₹ 1.95 Cr
- Revenue Growth 71.20%
- Profit Growth 571.78%
- Ebitda 356.67%
- Net Worth 28.49%
- Total Assets 6.63%
About Disto Pharmaceuticals
Disto Pharmaceuticals Private Limited (DPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 09 May 2002 and has a history of 22 years and nine months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.56 Cr.
The company currently has active open charges totaling ₹7.49 Cr. The company has closed loans amounting to ₹1.95 Cr, as per Ministry of Corporate Affairs (MCA) records.
Asith Mukherjee, Harish Pandey, Bidesh Mukherjee, and One other member serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239TG2002PTC038926
- Company No.
038926
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 May 2002
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Disto Pharmaceuticals Private Limited offer?
Disto Pharmaceuticals Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, API (Active Pharmaceutical Ingredients), Antipyretic and Analgesic API, Real Estate Agent & Property Dealers, Real Estate Services, Anti Infective API, FRP Lining, PU & Powder Coatings, Powder Coatings, Organic and Inorganic Solvents, Carboxylate Esters.
Who are the key members and board of directors at Disto Pharmaceuticals?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Asith Mukherjee ![]() | Managing Director | 15-Sep-2009 | Current |
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Harish Pandey ![]() | Director | 15-Sep-2009 | Current |
Bidesh Mukherjee ![]() | Whole-Time Director | 15-Oct-2022 | Current |
Krishna Pandey ![]() | Whole-Time Director | 15-Oct-2022 | Current |
Financial Performance of Disto Pharmaceuticals.
Disto Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 71.2% increase. The company also saw a substantial improvement in profitability, with a 571.78% increase in profit. The company's net worth Soared by an impressive increase of 28.49%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Disto Pharmaceuticals?
Unlock access to Disto Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Charges (Loans)
₹7.49 Cr
₹1.95 Cr
Charges Breakdown by Lending Institutions
- Uco Bank : 7.49 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
06 Dec 2021 | Uco Bank | ₹7.50 M | Open |
07 May 2021 | Uco Bank | ₹6.74 Cr | Open |
10 Oct 2019 | Uco Bank | ₹2.00 M | Satisfied |
04 Apr 2019 | State Bank Of India | ₹4.95 M | Satisfied |
09 May 2011 | Hdfc Bank Limited | ₹1.25 Cr | Satisfied |
How Many Employees Work at Disto Pharmaceuticals?
Disto Pharmaceuticals has a workforce of 75 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Disto Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Disto Pharmaceuticals's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.